FeNO - Help with your business case
Help to construct your business case to enable sustainable adoption of FeNO and also to think about areas of funding that might not have been considered
Making a case for change
In order to justify any investment on new services or equipment, it is important to make a case for change (business case), describe the intended impacts and outcomes of your project, and outline the costs and project plan to deliver it.
Wessex Academic Health Science Networks (AHSN) have created a template Case for Change to support clinical teams looking to implement FeNO testing at scale.
The economic literature on benefits resulting from FeNO implementation is limited – this Case for Change does not describe a causal effect nor does it describe an expected return on investment as a result of implementing FeNO testing in an asthma pathway.
If you have any questions or queries, please get in touch with your local AHSN who will be happy to support you with the development of your Case for Change.
Business case considerations
Eastern AHSN have developed a tool to help you think through the elements needed for a successful business case. Below is a summary of the elements to be considered and a link to access the tool. Thank you to Eastern AHSN for sharing this tool.
''A business case evaluates the benefit, cost and risk of strategic options and provides a rationale for the proposed solution. It contains all further information that a purchasing or commissioning manager would need, in order to leverage the funds for spending on a solution.
This information will help align an organisations’ strategy and governance structures. It will cover:
- Why the project is being run
- Expected benefits
- Current situation, alternative solutions and return on investment''
You can access the toolkit here following a short data capture page.
There are opportunities to gain funding for new clinical pathways and/or innovative practise through Pharma Grants. The ABPI Code of Practice sets out the requirements the pharmaceutical industry must comply with and supports companies commitment to self-regulation and to operate in a professional, ethical and transparent manner. It is worth noting that grants are not generally available for purchase of clinical products but are more appropriate for the supporting processes/clinical pathway transformation.
Here you can access more information around ABPI guidance on Pharma grants. The AHSN may be able to offer support with the application process if required.
Previous work in this area has highlighted potential for future savings in medicines. This is based on the improvement in diagnosis that FeNO provides and also the potential for ongoing disease management, preventing the prescribing of unnecessary medicines.
Here you can view a case study of the impact of FeNO diagnostics on medicines costs.
Wessex AHSN have developed a number of resources to support you to develop your FeNO project using QI methodology.